March 20, 2023: In a public comment, we explain our concerns about FDA’s plan to distribute user fee funding to non-governmental organizations to support premarket real world evidence (RWE).
Read More »On Health Policy
NCHR comments on AHRQ draft review on the management of postpartum hypertensive disorders of pregnancy
NCHR agrees with AHRQ draft review designed to enhance care for women with postpartum hypertensive disorders of pregnancy. We are encouraged by the focus on the important issue of maternal mortality and look forward to seeing a meaningful response by policymakers.
Read More »Meeting of Patient, Consumer, and Public Health Coalition with Commissioner Califf and Key FDA Officials
March 1, 2023: As a leader of the Patient, Consumer, and Public Health Coalition, the National Center for Health Research scheduled a meeting at the FDA with Commissioner Califf and other key FDA officials to discuss accelerated approval, lab developed diagnostic tests, and improvements to FDA Advisory Committees.
Read More »Patient, Consumer, and Public Health Coalition Letter to Congress on CMS Limited Coverage for Newly Approved Alzheimer’s Drugs
February 27, 2023: NCHR urges Congress to support the decision by the Centers for
Medicare and Medicaid Services (CMS) to limit the coverage of newly approved Alzheimer’s
drugs until the treatments have been shown to have a meaningful, clinical benefit that outweighs
the risks for the Medicare population.
Testimony of Dr. Diana Zuckerman before the House of Delegates Environment & Transportation Committee For HB 299
February 15, 2023: NCHR testified before the Maryland House Environment Committee to support HB299, which would require transparency about the use and disposal of artificial turf and infill. That will enable communities to make informed decisions about the environmental and health impact of these materials.
Read More »